Patent · US Active

Calcitonin gene-related peptide (CGRP) antagonist antibodies

US11629184B2 · kind B2 · utility

0Cited by

0References

16Claims

0Family size

Assignee

REMD Biotherapeutics, Inc. · US

Inventors

Frank J. Calzone · Westlake Village, US
John Zhang · New York, US

Key dates

Filing date	Feb 23, 2019
Grant date	Apr 18, 2023
Priority date	—
Expiry date	Feb 23, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind Calcitonin Gene Related Peptide (CGRP). These anti-CGRP antibodies, or antigen-binding fragments thereof, have a high affinity for CGRP, function to inhibit CGRP, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., a human) and can be used to treat CGRP-associated disorders, while avoiding the adverse side effects associated with the current CGRP antagonist therapies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.